硼替佐米联合地塞米松治疗多发性骨髓瘤的临床研究

本研究观察硼替佐米治疗多发性骨髓瘤的疗效及不良反应。7例初治患者均采用硼替佐米联合地塞米松治疗；另3例复发难治患者中2例采用硼替佐米联合地塞米松，1例同时加用米托蒽醌和沙利度胺治疗。结果显示，根据EMBT标准判定疗效，7例初治患者中1例完全缓解（CR），5例部分缓解（PR），1例轻微缓解（MR）；3例复发难治患者中2例部分缓解（PR），1例轻微缓解（MR）。总缓解率（CR＋PR）80％。3例患者在治疗过程中出现血小板减少，1例出现腹泻，1例足部麻木，经对症处理后均恢复。结论：硼替佐米治疗初发及复发难治多发性骨髓瘤均有较好的疗效，对治疗相关的副反应患者可耐受。

Clinical Study of Bortezomib in Combination with Dexamethasone for the Treatment of Multiple Myeloma

The objective of study was to evaluate the efficiency and safety of bortezomib for the treatment of multiple myeloma. Bortezomib in combination with dexamethasone was administered as first-line treatment in all 7 newly diagnosed patients with multiple myeloma. The patients with refractory myeloma were treated with bortezomib in combination with dexamethasone or with other traditional agents such as mitoxantrone and thalidomide. The results showed that according to the EMBT criteria, out of 7 patients one achieved complete response (CR), five achived partial response (PR) and one achived minor response (MR). The 3 patients with refractory/relapsed myeloma achieved PR (2/3) and MR (1/3). The overall response rate (CR + PR) was 80%. The most frequent adverse events observed were thrombocytopenia in three patients, diarrhea and peripheral neuropathy in one respectively. In conclusion, bortezomib demonstrates efficiency in the treatment of new-diagnosed and refractory/relapsed multiple myeloma, and the side effects from treatment are acceptable and manageable.